Richard G Vile

Author:

Richard G. Vile

ISBN #:

0471933333

Author:

Richard G. Vile

ISBN #:

0471952664

Author:

Richard Vile

ISBN #:

0830607684

Author:

Richard Vile

ISBN #:

0830651152

Author:

Richard Vile

ISBN #:

0830651772

Author:

Richard C. Vile

ISBN #:

0130391980

Author:

Richard C. Vile

ISBN #:

0130392065

Author:

Richard C. Vile

ISBN #:

0673188132

US Patent:

20020042127, Apr 11, 2002

Filed:

Nov 22, 1999

Appl. No.:

09/444802

Inventors:

STEPHEN JAMES RUSSELL - ROCHESTER MN, US
RICHARD VILE - ROCHESTER MN, US
ANDREW BATEMAN - ROCHESTER MN, US
ALAN MELCHER - ROCHESTER MN, US

International Classification:

A61K048/00
A01N063/00
C12N005/00
C12N005/06
C12N005/12
C12N015/02

US Classification:

435/346000, 435/449000

Abstract:

Disclosed is a cell which expresses a surface marker associated with a professional antigen presenting cell, and a fusogenic membrane protein, where the cell may also express at its surface a tumor cell marker. Also disclosed is a fusion hybrid formed by the fusion of a tumor cell and a professional antigen presenting cell (APC) such that the resulting fusion hybrid expresses an APC marker, a tumor cell marker, and a fusogenic membrane glycoprotein. Also disclosed are compositions comprising the cells and fusion hybrids, and methods of making and using the hybrids.

US Patent:

20020150556, Oct 17, 2002

Filed:

Mar 30, 2001

Appl. No.:

09/822634

Inventors:

Richard Vile - Rochester MN, US
Kevin Harrington - London, GB
Steven Murphy - Sudbury, GB
Andrew Bateman - London, GB

International Classification:

A61K048/00
C12N015/86
C12N005/08

US Classification:

424/093200, 435/456000, 435/366000, 435/320100

Abstract:

This invention relates to a recombinant nucleic acid vector comprising a first expression cassette comprising a first promoter operably linked to a nucleic acid sequence encoding a syncytium-inducing polypeptide, wherein the first expression cassette is flanked on either side by a site recognized by a recombinase. The invention also includes a second expression cassette comprising a tissue-specific promoter operably linked to a nucleic acid sequence encoding a recombinase. The invention also includes cells and compositions including these expression cassettes and methods of reducing tumor volume by expression of these expression cassettes.

US Patent:

20060121000, Jun 8, 2006

Filed:

Oct 31, 2003

Appl. No.:

10/533613

Inventors:

Richard Vile - Rochester MN, US
Atique Ahmed - Rochester MN, US

Assignee:

Mayo Foundation for Medical Education and Research - Rochester MN

International Classification:

A61K 48/00
C12N 15/86

US Classification:

424093200, 435456000

Abstract:

Viral vectors that include a nucleic acid encoding a therapeutic polypeptide operably linked to a heterologous destabilizing element are described.

US Patent:

20100292309, Nov 18, 2010

Filed:

Mar 7, 2008

Appl. No.:

12/530290

Inventors:

Richard G. Vile - Rochester MN, US
Timothy J. Kottke - Oronoco MN, US
Jose S. Pulido - Rochester MN, US
Jill M. Thompson - Stewartville MN, US
Alan Melcher - Leeds, GB

International Classification:

A61K 31/7088
C07H 21/04
C12N 15/63
A61P 35/00

US Classification:

514 44 R, 536 235, 536 232, 4353201

Abstract:

This document provides methods and materials related to treating cancer. For example, methods and materials that include using CD40L polypeptide, an hsp70 polypeptide, and a cytotoxic polypeptide to trigger an immune response directed against cancer cells are provided.

US Patent:

20120308601, Dec 6, 2012

Filed:

Feb 10, 2011

Appl. No.:

13/578224

Inventors:

Richard G. Vile - Rochester MN, US
Timothy J. Kottke - Oronoco MN, US
Jose S. Pulido - Rochester MN, US
Alan Melcher - Leeds, GB
Peter Selby - Leeds, GB

Assignee:

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN

International Classification:

A61K 31/7088
A61P 37/04
A61P 35/00
A61K 39/00
C12N 7/01

US Classification:

4241991, 4242771, 4352351

Abstract:

This document provides methods and materials related to treating cancer. For example, methods and materials for using nucleic acid libraries to treat cancer are provided.

US Patent:

6867036, Mar 15, 2005

Filed:

Nov 22, 2000

Appl. No.:

09/721391

Inventors:

Richard G. Vile - Rochester MN, US
Michael Gough - Rochester MN, US

Assignee:

Mayo Foundation for Medical Education and Research - Rochester MN

International Classification:

C12N015/00
C12N015/63
C07H021/04

US Classification:

4353201, 435455, 536 241

Abstract:

A nucleic acid construct is described which provides cell type-specific expression of a therapeutic transgene. The construct utilizes a cell type-specific promoter which drives expression of the transgene. A positive feedback loop is introduced through the addition of a amplification promoter element operably linked to the therapeutic transgene and by providing, either as part of the same construct, or in a different construct, a transcription activator for activating the amplification promoter element. In one embodiment, the amplification promoter element is a heat shock response element (HSE) and the transcription activator is HSF-1. The construct enables functional targeting of a therapeutic gene while avoiding undesirable effects in non-targeted cells, by combining sufficiently high-level expression to promote a desirable therapeutic outcome with exceptional tissue specificity. A series of promoter elements, constructs, vectors, and therapeutic approaches is presented for gene therapy of tumors such as melanoma and other genetic diseases.

US Patent:

20210275615, Sep 9, 2021

Filed:

Sep 13, 2019

Appl. No.:

17/275713

Inventors:

Laura EVGIN - Rochester MN, US
Richard G. VILE - Rochester MN, US
Luis SANCHEZ-PEREZ - Apex NC, US
- Rochester MN, US
- Durham NC, US

International Classification:

A61K 35/768
A61K 35/17
C12N 15/86
C07K 14/715
C07K 14/71
C07K 14/705

Abstract:

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using one or more oncolytic viruses (OVs) in combination with an adoptive cell therapy (e.g., a chimeric antigen receptor T cell therapy) to alter one or more functions of a T cell and/or to enhance T cell expansion to treat cancer in a mammal (e.g., a human) are provided.

US Patent:

20210030858, Feb 4, 2021

Filed:

Mar 29, 2019

Appl. No.:

16/975512

Inventors:

- Rochester MN, US
Richard G. Vile - Rochester MN, US
Timothy J. Kottke - Oronoco MN, US
Amanda L. Huff - Rochester MN, US

International Classification:

A61K 39/00
A61P 35/00

Abstract:

This document relates to methods and materials for treating a mammal having cancer. For example, compositions (e.g., vaccines) containing cells (e.g., tumor cells) expressing APOBEC3 which can be administered to a mammal (e.g., a human) having cancer to induce an immune response (e.g., an anti-tumor immune response) within the mammal are provided.